BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35976643)

  • 21. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
    Bossuyt V; Symmans WF
    Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.
    Provenzano E; Vallier AL; Champ R; Walland K; Bowden S; Grier A; Fenwick N; Abraham J; Iddawela M; Caldas C; Hiller L; Dunn J; Earl HM
    Br J Cancer; 2013 Mar; 108(4):866-72. PubMed ID: 23299526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
    Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Mátrai Z; Tóth L; Polgár C; Láng I; Gõdény M; Sinkovics I; Horváth Z; Bidlek M; Udvarhelyi N; Bartal A; Sávolt A; Ujhelyi M; Kásler M
    Magy Onkol; 2011 Jun; 55(2):73-84. PubMed ID: 21655472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Neoadjuvant Chemotherapy on Axillary Lymph Node Positivity and Numbers in Breast Cancer Cases.
    Uyan M; Koca B; Yuruker S; Ozen N
    Asian Pac J Cancer Prev; 2016; 17(3):1181-5. PubMed ID: 27039745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
    Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.
    Sun S; van la Parra RFD; Rauch GM; Checka C; Tadros AB; Lucci A; Teshome M; Black D; Hwang RF; Smith BD; Krishnamurthy S; Valero V; Yang WT; Kuerer HM
    Ann Surg Oncol; 2019 Oct; 26(10):3071-3079. PubMed ID: 31342361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
    Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
    Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postneoadjuvant Pure and Predominantly Pure Intralymphatic Breast Carcinoma: Case Series and Literature Review.
    MacColl CE; Paré G; Salehi A; Hodgson N; Williams P
    Am J Surg Pathol; 2021 Apr; 45(4):537-542. PubMed ID: 33105157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
    Rabban JT; Glidden D; Kwan ML; Chen YY
    Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pathologic complete response open question in primary therapy.
    Marchiò C; Sapino A
    J Natl Cancer Inst Monogr; 2011; 2011(43):86-90. PubMed ID: 22043049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Primary systemic therapy in breast cancer patients (2007-2010)].
    Zapf I; Tizedes G; Pavlovics G; Kovács G; Kálmán E; Szalai G; Kövér E; Farkas R; Horváth OP
    Magy Seb; 2011 Oct; 64(5):223-8. PubMed ID: 21997525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.
    Sahoo S; Lester SC
    Arch Pathol Lab Med; 2009 Apr; 133(4):633-42. PubMed ID: 19391665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Shrinkage mode of the primary breast tumor after neoadjuvant chemotherapy analyzed with part-mount sub-serial sectioning and three-dimensional reconstruction technique].
    Yang T; Zhang ZP; Sun XY; Liu G; Mu DB; Wang YS
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):270-6. PubMed ID: 27087373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
    Wang L; Li Y; Li J; Wang T; Xie Y; He Y; Fan Z; Ouyang T
    Clin Transl Oncol; 2021 Feb; 23(2):240-245. PubMed ID: 32519177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
    Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
    Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.